Format

Send to

Choose Destination
See comment in PubMed Commons below
Chin J Cancer. 2013 May;32(5):270-4. doi: 10.5732/cjc.013.10005. Epub 2013 Mar 15.

Impact of genetic alterations on mTOR-targeted cancer therapy.

Author information

  • 1Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA. ssun@emory.edu

Abstract

Rapamycin and its derivatives (rapalogs), a group of allosteric inhibitors of mammalian target of rapamycin (mTOR), have been actively tested in a variety of cancer clinical trials, and some have been approved by the Food and Drug Administration for the treatment of certain types of cancers. However, the single agent activity of these compounds in many tumor types remains modest. The mTOR axis is regulated by multiple upstream signaling pathways. Because the genes (e.g., PIK3CA, KRAS, PTEN, and LKB1) that encode key components in these signaling pathways are frequently mutated in human cancers, a subset of cancer types may be addicted to a given mutation, leading to hyperactivation of the mTOR axis. Thus, efforts have been made to demonstrate the potential impact of genetic alterations on rapalog-based or mTOR-targeted cancer therapy. This review will primarily summarize research advances in this direction.

[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Cancer Center,Sun Yat-sen University Icon for PubMed Central
    Loading ...
    Write to the Help Desk